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General cognitive function represents the ability to 
perform tasks across different cognitive domains. The 
development of the nervous system shapes an important 
part of  the  inter-individual  variation  in  cognitive  per- 
 
formance, with neurodegenerative processes in-
creasingly contributing later in life [1, 2]. As such, 
general cognition is a mixed construct consisting of 
both developmental and degenerative components 
[1], of which the neurodegenerative element may 
serve as an endophenotype for clinical outcomes such 





























Cognition  in adults  shows variation due  to developmental and degenerative  components. A  recent genome‐
wide association study identified genetic variants for general cognitive function in 148 independent loci. Here,
we  aimed  to  elucidate  possible  developmental  and  neurodegenerative  pathways  underlying  these  genetic
variants by relating them to functional, clinical and neuroimaging outcomes. This study was conducted within
the  population‐based  Rotterdam  Study  (N=11,496, mean  age  65.3±9.9  years,  58.0%  female). We  used  lead
variants  for  general  cognitive  function  to  construct  a  polygenic  score  (PGS),  and  additionally  excluded
developmental  variants  at  multiple  significance  thresholds.  A  higher  PGS  was  related  to  more  years  of
education  (β=0.29, p=4.3x10‐7) and a  larger  intracranial volume  (β=0.05, p=7.5x10‐4). To a smaller extent,  the
PGS was associated with  less cognitive decline  (βΔG‐factor=0.03, p=1.3x10
‐3), which became non‐significant after
adjusting  for  education  (p=1.6x10‐2).  No  associations  were  found  with  daily  functioning,  dementia,
parkinsonism,  stroke or microstructural white matter  integrity. Excluding developmental variants attenuated
nearly  all  associations.  In  conclusion,  this  study  suggests  that  the  genetic  variants  identified  for  general
cognitive  function are acting mainly  through  the developmental pathway of  cognition. Therefore,  cognition,
assessed cross‐sectionally, seems to have limited value as a biomarker for neurodegeneration. 
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as daily functioning, dementia, parkinsonism, and 
stroke. 
 
Recently, the highly polygenic architecture of general 
cognitive function was partly elucidated by the 
identification of 178 lead genetic variants in 148 
independent loci [3]. However, it is unclear whether 
these variants act through a developmental or neuro-
degenerative pathway. Elucidating these pathways 
could provide more insight into the underlying biology 
of cognition and its potential as an endophenotype for 
clinically relevant outcomes. A developmental pathway 
would be more likely when these variants are linked to 
markers of cognitive and brain reserve such as 
educational attainment. On the other hand, more evi-
dence for a neurodegenerative pathway would be gained 
when the variants are associated with clinical outcomes 
and brain imaging markers linked to neurodegeneration 
or accelerated cognitive decline. 
 
Thus, in this population-based study, we aimed to elu-
cidate the possible underlying pathways of the recently 
identified genetic variants for general cognitive func-
tion by exploring their associations with cognitive de-
cline, measures of daily functioning, the risk of neuro-




Genotyping data was available for 11,496 individuals 


























were women. A flowchart for the inclusion of par-
ticipants in the different analyses is shown in Figure 1. 
Table 1 contains an overview of the study population 
characteristics for the different analyses. 
 
Cognitive performance and daily functioning 
 
As a methodological validation, we looked whether a 
cross-sectional relation was present between the 
polygenic score (PGS) and cognition. Indeed, an 
increase in the PGS was significantly associated with a 
higher general cognitive performance (‘G-factor’) 
(β=0.08, p=1.2x10-13), as well as with individual 
cognitive tests (Figure 2A). The PGS was also 
significantly associated with more years of education 
(β=0.29, p=4.3x10-7). No associations with daily 
functioning were found. Adjusting for years of 
education caused an attenuation of the associations, 
yet only the associations for Stroop 1 became non-
significant. Nearly all associations attenuated after 
removing variants associated with the developmental 
component of cognition (Figure 2A, Supplementary 
Figure S1). To explore the developmental component 
further, we created a PGS of the same 170 genetic 
variants using the weights for educational attainment. 
This PGS showed similar associations with all 
cognitive tests. No individual variant was significant-
ly associated with any of the outcomes. All results for 
the cross-sectional analyses of cognition, daily func-


























 Figure  1.  Flowchart  presenting  the  in‐  and  exclusions  of  participants  in  the  different  analyses.  Abbreviations:  magnetic
resonance imaging (MRI). 
 



















Figure 2B shows that a higher PGS was associated with 
less cognitive decline (βΔG-factor=0.03, p=1.3x10-3), 
although  this association  became  non-significant  after  





















































1.6x10-2). A higher PGS was also associated with less 
decline in basic activities of daily living (BADL), 
although this was not significant after correcting for 




































time, as well as years of education, adjusted  for age and  sex with and without adjustment  for years of education  (A), and change  in
cognitive performance and daily functioning over time (B), additionally adjusted for baseline measurement and time between baseline
and follow‐up measurement. Three polygenic scores are presented: a cognition polygenic score  including all  independent  lead variants
(N=170); a  cognition polygenic  score only  including variants with a p>0.05  for  the association with  the developmental  component of
cognition, i.e. educational attainment and intracranial volume (N=36); and an educational attainment polygenic score, which contains the
lead genetic variants for cognitive performance (N=170) but uses the weights for educational attainment. Larger blocks indicate higher t‐
values.  Higher  scores  indicate  better  performance,  except  for  the  Stroop  test,  the  Basic  Activities  of  Daily  Living  and  Instrumental
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Age, years 64.0±9.1 64.0 (11.0) 64.8±9.5 72.0±8.0 64.6±9.4 69.2±8.7 64.9±9.7 70.7±8.8 65.1±9.8 70.4±8.7 










46.8 (59) 57.4 
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52.3 (135) 58.2 (6,436) 58.9 (718) 
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genetic variants associated with educational attainment 
and intracranial volume did not show a substantial 
enrichment of the effects. In contrast, the PGS for 
educational attainment even showed a slightly stronger 
association with cognitive decline than the cognition 
PGS (βΔG-factor=0.03, p=8.3x10-4) (Figure 2B, Supple-
mentary Figure S2). In the single-variant analysis, no 
variant reached statistical significance. MMSE measure-
ments were available in a larger sample (N=9,369) with 
up to six measurements and a maximum follow-up of 
25.2 years. In this sample, we observed a modest but 
significant relation between the PGS and yearly Mini-
Mental State Examination (MMSE) change using linear 
mixed models (β=3.5x10-3, p=4.3x10-4). Supplementary 
Table S4 contains the complete results for the lon-




No significant association was found between the PGS 
and any of the clinical outcomes (Figure 3). Out of all 
170 individual lead variants, none was significantly 
associated with the risk of one of dementia, 
parkinsonism or stroke. An increased risk for dementia 
was found after excluding variants associated with the 
developmental component at a p>0.05 threshold (hazard 
ratio 1.06, p=0.040), although this did not survive 
correction for multiple testing (Supplementary Figure 
S3). The PGS for educational attainment was not related 
to any of the neurological outcomes. Full results for the 
analyses of clinical outcomes are presented in Sup-

























Brain imaging markers 
 
We found that a higher PGS was significantly related to 
a larger intracranial volume (β=0.05, p=7.5x10-4), but 
not with the other volumetric measures or with global 
white matter microstructural integrity (Figure 4). At a 
nominal significance level, a higher PGS was associated 
with a higher fractional anisotropy (FA) in the medial 
lemniscus, and a lower mean diffusivity (MD) in the 
inferior-fronto-occipital fasciculus and the posterior 
thalamic radiation (minimal p=2.2x10-2), but this did 
not survive correction for multiple testing (Figure 5). 
Removing genetic variants associated with the 
developmental component of cognition did not show a 
pattern of enrichment of the associations. The 
associations between the educational attainment PGS 
with the brain imaging markers were comparable to 
those of the cognition PGS (Figure 4, Supplementary 
Figure S4-5). No individual variant reached the 
significance threshold for the association with any of 
the brain imaging markers after multiple comparisons 
correction. Full results of the brain imaging analyses 




In this population-based study among middle-aged and 
elderly persons, a PGS based on recently identified 
genetic variants for global cognition was associated 
with better global and test-specific cognitive per-
formance, more years of education and a larger 
intracranial volume. This PGS was also associated with 
measures of cognitive decline, although these 
associations attenuated after adjusting for educational 
attainment, and no enrichment of the effects was 
observed when we excluded variants associated with 
developmental cognitive components. We did not find 
significant associations with (decline in) daily function-
ing, the incidence of dementia, parkinsonism or stroke, 
or with other brain imaging markers.  
 
Cognitive decline is considered an important marker for 
the development and progression of neurodegenerative 
diseases [4-6]. However, we found that a higher cog-
nition PGS was mainly associated with a better 
cognitive performance cross-sectionally, and only to a 
limited extent longitudinally. In fact, a PGS of the same 
variants using the weights for educational attainment 
was equally or more associated with cognitive decline. 
In contrast, we did find associations with developmental 
components of cognition, i.e. educational attainment 




Figure  3.  Polygenic  scores  for  general  cognitive  function  and  disease‐free  probability  for  dementia,  parkinsonism  and
stroke. Kaplan‐Meier curves presenting the association between low (i.e. below the median) and high (above the median) polygenic scores
and the disease‐free probability over time for dementia, parkinsonism, and stroke. Abbreviations: polygenic score (PGS). 
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partially determined by genetics and are suggested to be 
protective against cognitive decline [7-10]. It is also 
seen as an explanation for interindividual differences in 
the clinical presentation of neurodegenerative diseases 
in patients with a similar neuropathology [11-13]. These 
findings are thus suggestive of a developmental path-
way underlying the genetic variants for cognitive 
performance.  
 
To our knowledge there are as yet no other studies that 
have investigated the association between these genetic 
variants and clinical outcomes. We found no significant 
relation between the PGS and the risk of dementia, 
parkinsonism or stroke. If anything, we observed a 
nominally significant association with the incidence of 
dementia after we excluded all genetic variants 
associated with the developmental cognitive component 
(p<0.05). However, the direction of effect was not as 
expected, i.e. a higher PGS – associated with better 
cognitive function – showed an increase in the risk of 
dementia. Yet, since this association did not survive 


































should be drawn from this finding, and validation in 
other studies is needed. Previous observational studies 
have shown associations between cognitive function 
and dementia, parkinsonism, Parkinson’s disease and 
stroke, both before and after diagnosis [5, 14-18]. Also, 
disease-specific genetic variants for these disorders 
have been associated with cognitive functioning [19-
22]. This may indicate that cognitive decline as seen in 
abovementioned (prodromal) clinical outcomes is 
mainly caused by disease-specific variants rather than 
variants for general cognitive function. However, we 
also did not find significant associations between the 
cognition PGS and diffusion magnetic resonance 
imaging (MRI) measures, in contrast to previous studies 
that showed associations between global and tract-
specific microstructural integrity and cognition and 
cognitive decline [23-26]. This may indicate that these 
associations are mainly driven by non-genetic com-
ponents. Another possibility is that our study did not 
have enough power to detect associations with the 
incidence of the clinical outcomes and neuroimaging 



































Figure  4.  Association  between  genetic  variants  for  general  cognitive  function  and  global  brain  imaging  markers.
Association between genetic variants for general cognitive function and both volumetric and global white matter microstructural integrity
markers. For the volumetric outcomes, analyses were adjusted for age and sex, and additionally for  intracranial volume  if the outcome






































genetic variants not seen on traditional structural 
neuroimaging; future studies on other imaging markers 
such as functional MRI could therefore prove useful 
information. Due to the absence of an association 
between the PGS and clinical outcomes and the modest 
association with cognitive decline, we attempted to 
enrich the degenerative component of the PGS by 
filtering out genetic variants that are associated with 
intracranial volume and educational attainment. By 
applying this filter, nearly all associations for the 
different analyses attenuated, supporting the suggestion 
that the genetic variants mainly represent the develop-
mental component of cognitive performance. However, 
removing genetic variants associated with the 
developmental component may also eliminate degene-
rative components of the PGS if some variants are 
pleiotropic, possibly leading to an underpowered study 
for detecting an effect of the PGS. A more robust 
method would be to perform a genome-wide association 
study (GWAS) with cognitive decline as an outcome 
instead of using cross-sectional measurements of 
cognitive performance, preferably in an elderly popula-
tion since neurodegeneration mainly occurs later in life. 
However, longitudinal measurements such as those in 
the present study are only available in a fraction of the 
samples with cross-sectional assessments, which at 






























Strengths of this study are the population-based setting, 
the longitudinal assessment of cognitive function and 
daily functioning, the availability of structural brain 
imaging, and the long follow-up period for dementia, 
parkinsonism and stroke. We also need to consider 
limitations. It should be noted that the Rotterdam Study 
was part of the discovery sample for the general cog-
nitive function, educational attainment and intracranial 
volume GWAS [3, 9, 27]. However, for cognitive 
function and educational attainment, this was only a 
small proportion of the total sample size (2.0% and 
1.4%, respectively), yet for ICV this was a larger 
percentage (18.2%). However, we only included 
genome-wide significant variants and these will most 
likely not be different if the Rotterdam Study would be 
excluded from the meta-analysis. Moreover, most 
variants were excluded due to their association with 
educational attainment (94.0%), thus we do not expect 
that this influenced our findings to a large extent. 
Another limitation is that the effect estimates in the 
summary statistics of the GWAS are based on the effect 
estimates of many different populations, and they may 
not be the correct estimates for the Dutch population as 
present in the Rotterdam Study. In addition, the self-
reported years of education may not be the best measure 
of educational attainment since the type and level of 
education is not taken into account. Also, cognitively 
impaired participants may not correctly recall their 
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received education, possibly creating noise in this 
variable. Furthermore, the mean follow-up time of 6.1 
years for the cognitive tests in this study is relatively 
short, which limits the power of detecting associations 
with cognitive decline. Additionally we assumed a 
linear decay of cognition over time. Despite this, we 
observed similar associations with cognitive decline 
when studying the association between the PGS change 
in MMSE using linear mixed models in a sample with 
up to six measurements. Selection bias may have 
occurred since cognitively impaired participants are less 
likely to visit the examination center, which may have 
caused an underestimation of the true association with 
cognitive decline. However, for the clinical outcomes, 
this selection bias is less likely to have occurred since 
the study database was linked to the participants’ 
medical records.  
 
In conclusion, we found that a PGS for general 
cognitive function was associated with cognitive 
performance, intracranial volume and educational at-
tainment, and to a limited extent with cognitive decline. 
We found no associations between the PGS and daily 
functioning, neurological disorders, or global brain 
tissue volumes and diffusion-MRI measurements. Using 
the weights of the educational attainment GWAS, 
similar associations were observed. Removing variants 
associated with developmental components of cognition 
did not cause a substantial enrichment of the asso-
ciations with neurodegenerative outcomes. Based on 
our results we postulate that the genetic variants 
identified for general cognitive function are acting 
mainly through the developmental pathway of cog-
nition. Therefore, cognition, assessed cross-sectionally, 
seems to have limited value as a biomarker for neuro-
degeneration. Future studies that focus on identifying 
genetic variants specific for cognitive decline are 
needed to help understand the pathophysiology 
underlying the degenerative component of cognition. 
 




This study was conducted within the Rotterdam Study, 
an ongoing population-based cohort study in the 
Netherlands with the aim to investigate causes and 
determinants of diseases in the elderly [28]. This cohort 
was initiated in 1990 and extended in 2000 and 2006, 
with a total of 14,926 participants aged 45 years and 
older who undergo examinations every three to four 
years. Assessment of dementia, parkinsonism and stroke 
has been performed since the start of the study. In 2002, 
an extensive cognitive test battery was added to the core 
protocol. MRI scanning was implemented in the study 
protocol from 2005 onwards [29]. Out of 14,926 
subjects, genotyping was successfully performed in 
11,496 participants. Figure 1 gives an overview of the 
selection of participants for the different analyses, 
presented in a flowchart. According to the Population 
Study Act Rotterdam Study, the Ministry of Health, 
Welfare and Sports of the Netherlands has given 
approval for the Rotterdam Study. All participants have 




Outcomes were selected based on their link with either 
development or neurodegeneration. Educational attain-
ment and intracranial volume (ICV) are established 
markers of cognitive and brain reserve and can therefore 
be used to study the developmental component of 
cognition [30, 31]. On the other hand, dementia, parkin-
sonism, and stroke are clinical outcomes related to 
accelerated cognitive decline and neurodegeneration [5, 
14-16]. Furthermore, daily functioning, global brain 
tissue volumes, and diffusion-MRI measurements have 
been associated with impaired cognition in the elderly 





The Illumina 550K, 550K duo and 610 quad arrays 
were used for genotyping. Samples with a call rate 
below 97.5% were removed, as well as gender 
mismatches, excess autosomal heterozygosity, duplica-
tes or family relations, ethnic outliers, variants with call 
rates lower than 95.0%, failing missingness test, Hardy-
Weinberg equilibrium p-value smaller than 10-6 and 
allele frequencies smaller than 1%. Genotypes were 
imputed using MaCH/minimac software to the 1000 




We calculated a PGS using the lead genetic variants 
with their corresponding effect sizes for general 
cognitive function [3]. Genetic variants that were not 
available in the reference panel and variants with an 
r2<0.30 were excluded (N=7 and N=1, respectively). 
For the remaining genetic variants (N=170), the allele 
dosage was multiplied by the reported effect estimate 
(Supplementary Table S1). Subsequently, the weighted 
effects of all variants were added up and the resulting 
PGSs were standardized into Z-scores. 
 
Since we aimed to differentiate the developmental com-
ponent of general cognitive function from degenerative 
effects, we calculated additional PGSs where variants 
associated with educational attainment and intracranial 
volume were removed at multiple p-value thresholds. 
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For each variant, we used the lowest p-value threshold 
for either educational attainment or intracranial volume. 
The p-values were extracted from the summary 
statistics of a GWAS on educational attainment 
performed in a discovery sample of 766,345 individuals 
[27], and a GWAS on intracranial volume performed in 
a discovery sample of 26,577 individuals [32]. The 
different p-value thresholds for the association with 
educational attainment and intracranial volume, with the 
corresponding number of variants that remained, as well 
as the explained variance of the G-factor in our dataset 
are shown in Supplementary Table S2. When applying 
the strictest p-value threshold for the exclusion of 
developmental variants (p>0.05), 36 genetic variants 
remained.  
 
Additionally, to explore the developmental component 
of the lead genetic variants for general cognitive 
function further, we created PGSs of the same 170 
variants using the weights of the educational attainment 
GWAS (Supplementary Table S1).  
 
Cognitive test battery 
 
For the cognition and daily functioning analyses, only 
participants who had two measurements for at least one 
of the tests underlying these outcomes were included. 
The MMSE was assessed as a measure of global 
cognitive function, and was collected since the initiation 
of the Rotterdam Study. From 2002 onwards, cognitive 
function was additionally assessed using multiple 
cognitive tests: the 15-word verbal learning test (15-
WLT), the Stroop test (consisting of reading, color 
naming and interference tasks, error-adjusted scores), 
the letter-digit substitution task (LDST), the verbal 
fluency test (using animal categories) and the Purdue 
pegboard (PPB) test for the left hand, right hand and 
both hands [2, 33-36]. A measure of general cognitive 
function (‘G-factor’) was obtained through principal 
component analysis on the delayed recall score of the 
15-WLT, Stroop interference test, LDST, verbal fluency 
task and the PPB test, as described previously [2]. The 
G-factor explained 53.4% and 51.9% of the variance in 
cognitive test scores in our population at baseline and 
follow-up visit, respectively. Z-scores were calculated 
in order to make comparable test results.  
 
Self-reported years of education was used as a measure 
of educational attainment. 
 
Assessment of daily functioning 
 
Two components of daily functioning were assessed: 
BADL and instrumental activities of daily living 
(IADL). The Dutch version of the Stanford Health 
Assessment Questionnaire was used to measure BADL 
(37), and IADL was measured using the Dutch version 
of the IADL scale [38]. To prevent selective loss of 
data, IADL items scored as non-applicable were 
imputed using the variables age, sex, BADL scores and 
all other available IADL items. Both BADL and IADL 
scores were standardized into Z-scores.  
 
Assessment of clinical outcomes 
 
The assessment of dementia, parkinsonism (including 
Parkinson’s disease) and stroke have previously been 
described in detail (39-41). In summary, history of these 
clinical outcomes was assessed during the baseline 
interview. Participants were screened at baseline and 
subsequent center visits for dementia with the MMSE 
and the Geriatric Mental Schedule organic level, and for 
signs of parkinsonism. Participants with a positive 
screening were further examined and were evaluated by 
a panel led by an experienced neurologist who made the 
definitive diagnosis. After enrollment, participants were 
continuously monitored for dementia, parkinsonism and 
stroke through automated linkage of the study database 
with files from general practitioners. Follow-up for 
parkinsonism (including Parkinson’s disease) was 
available until the 1st January 2015 and for dementia 
and stroke until the 1st January 2016. 
 
MRI acquisition and processing 
 
We performed a multi-sequence brain MRI scan on a 
1.5 tesla research dedicated MRI scanner (GE Signa 
Excite). Imaging details are provided elsewhere [29]. In 
short, the scan protocol included a T1-weighted image, 
a T2-weighted fluid-attenuated inversion recovery 
(FLAIR) sequence, a proton density weighted image 
and a spin echo echo planar diffusion weighted image 
for the diffusion-MRI. A multimodal algorithm was 
used based on T1-weighted, T2-weighted and FLAIR 
images to segment voxels into grey matter, white 
matter, white matter lesion volume, cerebrospinal fluid 
and background tissue using a k-nearest-neighbor-
algorithm trained on six manually labelled atlases [42, 
43]. We estimated supratentorial intracranial volume by 
summing total grey and white matter volume and 
cerebrospinal fluid [42].  
 
For the diffusion-MRI, three volumes were performed 
without diffusion weighting of which the average was 
used (b-value=0 s/mm2, maximum b-value was 1000 
s/mm2). Diffusion tensors were computed using 
ExploreDTI to obtain FA and MD in normal-appearing 
white matter voxels. We segmented fifteen white matter 
tracts using probabilistic tractography and atlas-based 
masking [44]. Tracts were grouped based on anatomic 
location or presumed function into brain stem tracts, 
projection tracts, association tracts, limbic system tracts 
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and callosal tracts. Tract-specific FA and MD but also 
white matter volumes and white matter lesion volumes 
in specific tracts were obtained as previously described 
[44]. In general, a lower FA and a higher MD are 





Linear regression models were used to assess the 
associations between the PGS and cognition, daily 
functioning, volumetric brain outcomes and white 
matter microstructural integrity. For the cross-sectional 
analysis of cognition and daily functioning we analyzed 
the first measurement. We additionally assessed the 
association with change in MMSE using linear mixed 
models with an interaction between the PGS and time. 
We used a random intercept and slope for time and 
included participants with a minimum of two MMSE 
measurements. Cox proportional hazard models were 
used to study the association between the PGS and the 
incidence of dementia, parkinsonism, and stroke. The 
proportional hazards and linearity assumptions were 
met. All models were adjusted for age and sex. Models 
assessing cognition and daily functioning were per-
formed with and without adjustment for educational 
attainment. Longitudinal cognition and daily functional 
analyses were adjusted for time between baseline and 
follow-up visit, and additionally for baseline measure-
ments in the linear regression analyses. Volumetric 
brain outcomes were adjusted for intracranial volume 
when the outcome was not intracranial volume, and 
additionally for white matter and white matter lesion 
volume in the analyses for white matter microstructural 
integrity. The abovementioned analyses were repeated 
for all genetic variants separately.  
 
Since outcomes for the different analyses may be 
correlated, we used permutation testing in order to 
assess the number of independent outcomes for each 
subsection. Based on this information, we defined the 
multiple testing p-value thresholds for the different 
analyses, namely p<0.0038 for the cross-sectional and 
p<0.0040 for the longitudinal analyses of cognitive 
performance and daily functioning; p<0.0101 for the 
volumetric and global diffusion-MRI brain measures, 
and p<0.0022 for the tract-specific diffusion-MRI 
analyses; and p<0.0129 for the clinical outcomes. For 
the analyses of the genetic variants separately, we 
additionally used the Bonferroni correction for multiple 
testing, using the formula k/170 with k representing the 
p-value threshold as obtained by permutation testing. 
Analyses were performed using the IBM SPSS 




15-WLT: 15-word verbal learning test; BADL: basic 
activities of daily living; FA: fractional anisotropy; 
GWAS: genome-wide association study; IADL: 
instrumental activities of daily living; LDST: letter-digit 
substitution task; MD: mean diffusivity; MMSE: Mini-
Mental State Examination; MRI: magnetic resonance 
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Supplementary  Figure  S3.  Association  between  polygenic  scores  for  general  cognitive
performance and the risk of neurologic disorders. 
 














































































































































Please browse the links in Full Text version to see the 
data related to this manuscript: 
 
Supplementary Table S1. Genetic variants used for 
constructing polygenic scores, with their corresponding 
summary statistics. 
 
Supplementary Table S2. P-value thresholds for the 
association with educational attainment and intracranial 
volume, and corresponding number of genetic variants 
remaining, as well as the explained variance for the G-
factor. 
 
Supplementary Table S3. Association of polygenic 
risk scores and individual genetic variants with 




























Supplementary Table S4. Association of polygenic 
risk scores and individual genetic variants with change 
in cognitive and daily functioning. 
 
Supplementary Table S5. Association of polygenic 
risk scores and individual genetic variants with clinical 
outcomes, adjusted for age and sex. 
 
Supplementary Table S6. Association of polygenic 
risk scores and individual genetic variants with 
volumetric brain imaging markers and global white 
matter microstructural integrity. 
 
Supplementary Table S7. Association of polygenic 
risk scores and individual genetic variants with tract-




Supplementary  Figure  S5.  Association  between  polygenic  scores  for general  cognitive  performance  and tract‐specific
microstructural integrity. 
